Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. [electronic resource]
Producer: 20130522Description: 19-29 p. digitalISSN:- 1941-837X
- Antibodies, Monoclonal, Humanized -- economics
- Bone Neoplasms -- drug therapy
- Cost-Benefit Analysis
- Denosumab
- Diphosphonates -- economics
- Disease Progression
- Health Expenditures -- statistics & numerical data
- Humans
- Imidazoles -- economics
- Male
- Markov Chains
- Models, Econometric
- Prostatic Neoplasms -- pathology
- Quality of Life
- Quality-Adjusted Life Years
- Survival Analysis
- United States
- Zoledronic Acid
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.